MedTrace Logo

An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer

NCT01161173 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 347

Last updated 2016-03-28

Study results available
· View outcomes & findings →

Summary

This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC). Data will be collected from patients who have received 1 course of standard systemic chemotherapy, experienced disease progression, and who are receiveingTarceva in a second-line setting. Patients will also be followed through third-line treatment if there is disease progression on Tarceva therapy.

Conditions

  • Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

DRUG

Erlotinib

Erlotinib was provided in the retail versions of the product.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Belgium
  • Luxembourg

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01161173 on ClinicalTrials.gov